Kirkland & Ellis Advises Bristol-Myers Squibb on its Acquisition of Flexus Biosciences, Inc.

Kirkland & Ellis LLP represented Bristol-Myers Squibb which today announced it has acquired Flexus Biosciences, Inc., a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics.  The transaction has a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million.

The Kirkland team is led by partner Daniel Wolf and by associate Laura Sullivan.
 
For more information please click here.